Revolution Medicines

Revolution Medicines company information, Employees & Contact Information

We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses.

Company Details

Employees
737
Founded
-
Address
700 Saginaw Dr.,, Redwood City,california 94063,united States
Email
in****@****nes.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Redwood City, California
Looking for a particular Revolution Medicines employee's phone or email?

Revolution Medicines Questions

News

Did Leadership Moves Just Shift Revolution Medicines' (RVMD) Investment Narrative Ahead of Key Launches? - Yahoo Finance

Did Leadership Moves Just Shift Revolution Medicines' (RVMD) Investment Narrative Ahead of Key Launches? Yahoo Finance

Revolution Medicines Awarded Voucher for Daraxonrasib - GlobeNewswire

Revolution Medicines Awarded Voucher for Daraxonrasib GlobeNewswire

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug - Reuters

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug Reuters

Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm Sold (NASDAQ:RVMD) - Seeking Alpha

Revolution Medicines: Shares Soar On Pancreatic Cancer Study Win - I'm Sold (NASDAQ:RVMD) Seeking Alpha

Assessing Revolution Medicines After Recent Cancer Breakthrough and 15% Monthly Rally - Yahoo Finance

Assessing Revolution Medicines After Recent Cancer Breakthrough and 15% Monthly Rally Yahoo Finance

Revolution Medicines’ Surging Potential: What’s Happening? - StocksToTrade

Revolution Medicines’ Surging Potential: What’s Happening? StocksToTrade

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug - Benzinga

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug Benzinga

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer - GlobeNewswire

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer GlobeNewswire

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History - Seeking Alpha

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History Seeking Alpha

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress - Yahoo Finance

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress Yahoo Finance

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib - GlobeNewswire

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib GlobeNewswire

Revolution Medicines: Overpriced RAS-Addicted Cancers Maven (NASDAQ:RVMD) - Seeking Alpha

Revolution Medicines: Overpriced RAS-Addicted Cancers Maven (NASDAQ:RVMD) Seeking Alpha

Oppenheimer Reaffirms Outperform on Revolution Medicines (RVMD) Amid RAS Therapy Progress - Yahoo Finance

Oppenheimer Reaffirms Outperform on Revolution Medicines (RVMD) Amid RAS Therapy Progress Yahoo Finance

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewswire

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma GlobeNewswire

Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer - Yahoo Finance

Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer Yahoo Finance

Revolution Medicines and Iambic Announce Technology and - GlobeNewswire

Revolution Medicines and Iambic Announce Technology and GlobeNewswire

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations - GlobeNewswire

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations GlobeNewswire

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewswire

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress GlobeNewswire

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting - GlobeNewswire

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress - GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress GlobeNewswire

Revolution Medicines: New Data Underscore A True Cancer Revolution (Upgrade) - Seeking Alpha

Revolution Medicines: New Data Underscore A True Cancer Revolution (Upgrade) Seeking Alpha

Revolution Medicines: Risky Buy On Recent Share Price Dip (NASDAQ:RVMD) - Seeking Alpha

Revolution Medicines: Risky Buy On Recent Share Price Dip (NASDAQ:RVMD) Seeking Alpha

REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers - PR Newswire

REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers PR Newswire

Why Revolution Medicines Stock Is Crashing Today - The Motley Fool

Why Revolution Medicines Stock Is Crashing Today The Motley Fool

Revolution Medicines, Inc. to Acquire EQRx, Inc. in - GlobeNewswire

Revolution Medicines, Inc. to Acquire EQRx, Inc. in GlobeNewswire

Revolution Medicines IPO Brings in $238 Million to Support Cancer Programs - BioSpace

Revolution Medicines IPO Brings in $238 Million to Support Cancer Programs BioSpace

Revolution Medicines tees up for oncology IND with $56M series B - Fierce Biotech

Revolution Medicines tees up for oncology IND with $56M series B Fierce Biotech

Revolution Medicines to acquire Warp Drive - Chemical & Engineering News

Revolution Medicines to acquire Warp Drive Chemical & Engineering News

Revolution Medicines - Chemical & Engineering News

Revolution Medicines Chemical & Engineering News

Top Revolution Medicines Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant